Duchenne muscular dystrophy: Current knowledge, treatment, and future prospects

Clinical Orthopaedics and Related Research

Volumn 401, Issue , 2002, Pages 88-106

  Biggar, W Douglas ^a   Klamut, Henry J ^a   Demacio, Paula C ^a   Stevens, Daniel J ^a   Ray, Peter N ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PREDNISONE; UTROPHIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BECKER MUSCULAR DYSTROPHY; CELL TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; GENE MUTATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GERM LINE; LONG TERM CARE; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; MUSCLE FUNCTION; MUSCLE NECROSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0036331154     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-200208000-00012     Document Type: Conference Paper

References (190)

1. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants
2. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer
3. Absence of alpha-syntrophin leads to structurally aberrant neuromuscular synapses deficient in utrophin
4. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle
5. Telomere length predicts replicative capacity of human fibroblasts
6. A role for nitric oxide in muscle repair: Nitric oxide-mediated activation of muscle satellite cells
7. Deflazacort in Duchenne dystrophy: Study of long-term effect
8. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoprotein complex
9. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide
10. Cloning and characterization of alternatively spliced isoforms of Dp71
11. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition
12. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
13. Decline in respiratory function and experience with long-term assisted ventilation in advanced Duchenne's muscular dystrophy
14. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
15. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
16. Different distributions of dystrophin and related proteins at nerve-muscle junctions
17. Deflazacort treatment of Duchenne muscular dystrophy
18. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy
19. Cognitive functions in Duchenne muscular dystrophy: A reappraisal and comparison with spinal muscular atrophy
20. Structure and function of telomeres
21. Telomerases
22. Beta-dystrobrevin, a member of the dystrophin-related protein family
23. Defective myoblasts identified in Duchenne muscular dystrophy
24. Aging normal and dystrophic mouse muscle: Analysis of myogenicity in cultures of living single fibers
25. Extension of life-span by introduction of telomerase into normal human cells
26. The role of agrin in synapse formation
27. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains
28. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy
29. Cognitive impairment in Duchenne muscular dystrophy
30. Clinical investigation in Duchenne dystrophy: 2: Determination of the "power" of therapeutic trials based on the natural history
31. Clinical investigation of Duchenne muscular dystrophy: Interesting results in a trial of prednisone
32. Dystrophin-associated proteins and the muscular dystrophies
33. Association of dystrophin and an integral membrane glycoprotein
34. The muscle satellite cell: A review
35. A novel 87,000-.Mr protein associated with acetylcholine receptors in Torpedo electric organ and vertebrate skeletal muscle
36. Muscular dystrophy in mdx mice despite lack of neuronal nitric oxide synthase
37. Deletion analysis of the dystrophin-actin binding domain
38. The catalytic subunit of yeast telomerase
39. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity
40. mdx muscle pathology is independent of nNOS perturbation
41. A novel dystrophin isoform is required for normal retinal electrophysiology
42. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
43. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo
44. Prednisone treatment in Duchenne muscular dystrophy: Long-term benefit
45. Prednisone in Duchenne muscular dystrophy
46. Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro
47. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo
48. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
49. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
50. Membrane organization of the dystrophin-glycoprotein complex
51. A role for the dystrophinglycoprotein complex as a transmembrane linker between laminin and actin
52. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy
53. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy
54. Muscle regeneration by bone marrow-derived myogenic progenitors
55. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis
56. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles
57. Identification of the mouse muscle 43,000-dalton acetylcholine receptor-associated protein (RAPsyn) by cDNA cloning
58. Peripheral proteins of postsynaptic membranes from Torpedo electric organ identified with monoclonal antibodies
59. Syntrophins: Modular adapter proteins at the neuromuscular junction and the sarcolemma
60. A postsynaptic Mr 58,000 (58K) protein concentrated at acetylcholine receptor-rich sites in Torpedo electroplaques and skeletal muscle
61. Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice
62. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins
63. Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin receptor
64. Rapsyn clusters and activates the synapse-specific receptor tyrosine kinase MuSK
65. Agrin acts via a MuSK receptor complex
66. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin
67. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice
68. Methods for construction of adenovirus vectors
69. Pre-clinical screening of drugs using the mdx mouse
70. Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)
71. Prevention by anti-LFA-1 of acute myoblast death following transplantation
72. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation
73. Dystrophin expression in the mdx mouse restored by stem cell transplantation
74. Clinical implications of maximal respiratory pressure determinations for individuals with Duchenne muscular dystrophy
75. Synaptic structure and development: The neuromuscular junction
76. Telomeres shorten during ageing of human fibroblasts
77. Examining potential drug therapies for muscular dystrophy utilising the dy/dy mouse: I: Clenbuterol
78. The limited in vitro lifetime of human diploid cell strains
79. A role for dystroglycan in basement membrane assembly
80. Dystroglycan inside and out
81. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
82. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin
83. High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: Prolongation of expression with immunosuppression
84. Targeted disruption of the neuronal nitric oxide synthase gene
85. Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan
86. Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles
87. Gene transfer into skeletal muscles by isogenic myoblasts
88. Human myoblast transplantation in immunodeficient and immunosuppressed mice: Evidence of rejection
89. High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice
90. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix
91. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
92. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan
93. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
94. Problems and potential for gene therapy in Duchenne muscular dystrophy
95. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
96. Myoblast transplantation in monkeys: Control of immune response by FK506
97. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression
98. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells
99. A muscle-specific enhancer within intron 1 of the human dystrophin gene is functionally dependent on single MEF-1/E box and MEF-2/AT-rich sequence motifs
100. Identification of a transcriptional enhancer within muscle intron 1 of the human dystrophin gene
101. Molecular and functional analysis of the muscle-specific promoter region of the Duchenne muscular dystrophy gene
102. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
103. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
104. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
105. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer: An alternative strategy for ex vivo gene therapy of primary myopathies
106. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing
107. Coenzyme Q deficiency in mitochondria: Kinetic saturation versus physical saturation
108. Telomere end-replication problem and cell aging
109. Developmental fate of skeletal muscle satellite cells
110. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice
111. Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases
112. Deflazacort: A review of its pharmacological properties and therapeutic efficacy
113. Difference in antioxidant activity between reduced coenzyme Q9 and reduced coenzyme Q10 in the cell: Studies with isolated rat and guinea pig hepatocytes treated with a water-soluble radical initiator
114. Lipofection of a cDNA plasmid containing the dystrophin gene lowers intracellular free calcium and calcium leak channel activity in mdx myotubes
115. Profiles of neuromuscular diseases: Duchenne muscular dystrophy
116. MyoD is required for myogenic stem cell function in adult skeletal muscle
117. Myoblast transfer in the treatment of Duchenne's muscular dystrophy
118. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy
119. Anti-inflammatory effect of transforming growth factor-beta 1 in myoblast transplantation
120. Steroids in Duchenne muscular dystrophy: Deflazacort trial
121. Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts
122. Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene
123. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
124. Long-term persistence and migration of myogenic cells injected into pre-irradiated muscles of mdx mice
125. Decreased breakdown of muscle protein after prednisone therapy in Duchenne dystrophy (DD)
126. Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex
127. The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy
128. The telomerase reverse transcriptase: Components and regulation
129. The spread of transgene expression at the site of gene construct injection
130. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells
131. Prednisone therapy for Duchenne's muscular dystrophy
132. Towards an understanding of the dystrophin-glycoprotein complex: Linkage between the extracellular matrix and the membrane cytoskeleton in muscle fibers
133. A theory of marginotomy: The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon
134. The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes
135. Myoblast-based gene therapies
136. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts
137. Beta-dystrobrevin, a new member of the dystrophin family: Identification, cloning, and protein associations
138. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice
139. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform
140. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides
141. Deflazacort vs. prednisone in Duchenne muscular dystrophy: Trends of an ongoing study
142. Respiratory function in the muscular dystrophies
143. Alteration in calcium handling at the subcellular level in mdx myotubes
144. Dystrophins in vertebrates and invertebrates
145. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin
146. Dystrophin and its isoforms
147. Dystrobrevin and dystrophin: An interaction through coiled-coil motifs
148. Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo
149. Development of the vertebrate neuromuscular junction
150. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
151. First meeting of the Duchenne Parent Project in Europe: Treatment of Duchenne Muscular Dystrophy. 7-8 November 1997, Rotterdam, The Netherlands
152. Satellite cells in normal, regenerating and dystrophic muscle
153. Specific interaction between the syntrophin PDZ domain and voltage-gated sodium channels
154. Localization of dystrophin relative to acetylcholine receptor domains in electric tissue and adult and cultured skeletal muscle
155. Transplantation of normal and DMD myoblasts expressing the telomerase gene in SCID mice
156. Telomerase allows the immortalization of T antigen-positive DMD myoblasts: A new source of cells for gene transfer application
157. Characterization of the ocular phenotype of Duchenne and Becker muscular dystrophy
158. Progress in myoblast transplantation: A potential treatment of dystrophies
159. Physiology of nitric oxide in skeletal muscle
160. Myoblasts, satellite cells, and myoblast transfer
161. Creatine monohydrate increases strength in patients with neuromuscular disease
162. Expression of the dystrophin isoform Dp71 in differentiating human fetal myogenic cultures
163. Calpains and muscular dystrophies
164. Expression of full-length utrophin prevents muscular dystrophy in mdx mice
165. Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice
166. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy
167. Liposome-mediated gene transfer into normal and dystrophin-deficient mouse myoblasts
168. Receptor tyrosine kinase specific for the skeletal muscle lineage: Expression in embryonic muscle, at the neuromuscular junction, and after injury
169. TRF2 protects human telomeres from end-to-end fusions
170. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
171. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin
172. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model
173. Expression of the N-terminal domain of dystrophin in E. coli and demonstration of binding to F-actin
174. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapy
175. The MyoD family and myogenesis: Redundancy, networks, and thresholds
176. Direct gene transfer into mouse muscle in vivo
177. Telomere positional effects and the regulation of cellular senescence
178. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy
179. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injection
180. SH3 domain-mediated interaction of dystroglycan and Grb2
181. Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin
182. Human endothelial cell life extension by telomerase expression
183. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
184. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy
185. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo
186. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice
187. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle